Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide for Gastroprotection in AF Patients on DOACs (REGATA)
NCT07354230Phase 4Completed
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rebamipide in gastritis, peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Pirogov Russian National Research Medical University. Primary endpoint: Composite endpoint at 24 weeks. Started Jan 2022; status: completed.
02
Drugs
rebamipide
03
Conditions
gastritispeptic ulcer disease (PUD)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07354230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354230.